Latest Articles

Publication Date
Effects of E2/ERβ on follicular granulosa cells and on AMH/Smad signalling in endometriosis.

Patients with endometriosis have greater risk of infertility, which is associated with compromised ovarian function. Dysfunction in follicular granulosa cells and hyperactivation of oestrogen receptor beta (ERβ) are evident in …

Published: March 6, 2026, midnight
FOGSI Consensus Redefines Endometriosis Care with Oral GnRH Antagonist, Elagolix - Medical Dialogues

FOGSI Consensus Redefines Endometriosis Care with Oral GnRH Antagonist, Elagolix Medical Dialogues

Published: Jan. 2, 2026, 6:13 a.m.
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …

Published: Dec. 20, 2025, midnight
The role of pharmacotherapy in the treatment of endometriosis: an update.

Endometriosis is a chronic inflammatory condition affecting ~10% of reproductive-age individuals and contributing significantly to infertility, pain, and reduced quality of life. Since our 2020 review, new pharmacologic strategies, updated …

Published: Dec. 2, 2025, midnight
Relugolix's impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes.

Relugolix offers a promising alternative for endometriosis-associated pain, yet its comprehensive impact on health-related quality of life (HRQoL), particularly as measured by the disease-specific EHP-30 questionnaire, remains underexplored.

Published: Sept. 29, 2025, midnight
Natural Pregnancy Following Oocyte Retrieval in a Luteal-Phase Progestin-Primed Ovarian Stimulation (PPOS) Protocol With Concurrent Blastocyst Cryopreservation: A Case Report.

Ovarian stimulation is used in assisted reproductive technology to help infertile couples achieve pregnancy. Luteal-phase stimulation with progestin-primed ovarian stimulation (PPOS) is a practical approach, as it involves oral medication …

Published: Aug. 17, 2025, midnight
GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight - The Malaysian Reserve

GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight The Malaysian Reserve

Published: Aug. 13, 2025, 10:08 p.m.
GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight - PR Newswire UK

GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight PR Newswire UK

Published: Aug. 13, 2025, 9:31 p.m.
Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.

Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …

Published: July 28, 2025, midnight
Prolonged oral GnRH-antagonist administration before euploid embryo transfer in patients with endometriosis: a prospective randomized pilot non-inferiority trial.

Is oral administration of a gonadotrophin releasing hormone (GnRH) antagonist for 2 months before euploid embryo transfer in patients with endometriosis non-inferior to intramuscular administration of a long-acting GnRH agonist …

Published: July 11, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!